Title:
ANGLOGENIC INHIBITOR
Document Type and Number:
Japanese Patent JPH01279828
Kind Code:
A
Abstract:
PURPOSE: To obtain an angiogenesis inhibitor containing fumagillin as active ingredient, and useful for preventing/treating various diseases involving the abnormal sthenia of angiogenesis in mammals such as diabetic retinopathy, ocular tumor, suppurative sarcoma, and rheumatic arthritis. CONSTITUTION: This inhibitor contains fumagillin or a pharmaceutically permissible salt thereof (e.g. sodium salt, potassium salt) as active ingredient, and pref. furthermore, angiogenesis inhibitory effect potentiator(s) such as heparin, sulfated cyclodextrin (esp. β-cyclodextrin tetradecasulfate. When to be put to use, this inhibitor can be safely administered orally or parenterally in the form of tablets or capsules or through injection. In general, the weight ratio of the potentiator to the fumagillin is about (1:10) to (3011)[pref. (1:3) to (10:1)].
Inventors:
FOLKMAN JUDAH (US)
INGBER DONALD (US)
FUJITA TAKESHI (JP)
KANAMARU TSUNEO (JP)
INGBER DONALD (US)
FUJITA TAKESHI (JP)
KANAMARU TSUNEO (JP)
Application Number:
JP596889A
Publication Date:
November 10, 1989
Filing Date:
January 17, 1989
Export Citation:
Assignee:
TAKEDA CHEMICAL INDUSTRIES LTD (JP)
CHILDRENS MEDICAL CENTER (US)
CHILDRENS MEDICAL CENTER (US)
International Classes:
C07D303/16; A61K31/335; A61K31/336; A61K31/395; A61K31/57; A61K38/18; A61K47/48; A61L27/36; A61L27/54; A61P9/00; C07D303/24; C07K14/50; C08B37/16; (IPC1-7): A61K31/335; C07D303/16
Attorney, Agent or Firm:
Akitoshi Otawa (1 outside)